Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

相似書籍

• Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-Small-Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599
  由: Brahmer, Julie R., et al.
  出版: (2011)
• Prognostic Models to Predict Survival in Non-Small Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab
  由: Hoang, Tien, et al.
  出版: (2012)
• Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab
  由: Sandler, Alan B., et al.
  出版: (2009)
• Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials
  由: Langer, Corey J., et al.
  出版: (2016)
• Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)
  由: Hanna, Nasser H., et al.
  出版: (2015)